CD20 Knockout Raji/Luciferase Cell Line

Description

CD20 Knockout Raji/Luciferase Cell Line is a genetically engineered B-lymphocyte model derived from Raji cells (a human Burkitt’s lymphoma line) featuring dual modifications: stable integration of luciferase (Luc) reporter gene and complete knockout of CD20 (MS4A1) expression. This cell line maintains characteristic Raji cell morphology and growth properties while providing sensitive bioluminescence detection capability for in vivo tracking and quantitative tumor burden assessment. The CD20 knockout eliminates target expression for anti-CD20 therapies (e.g., rituximab), making this line particularly valuable for immunotherapy resistance studies, engineered CAR-T cell validation, and investigation of alternative B-cell targeting strategies. Cells exhibit stable luciferase expression across passages (<P20) with consistent growth kinetics, enabling longitudinal studies in xenograft models. The cell line is rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, Fungi, Yeast and Bacteria.